List of Figures

Figure 1: a) Anatomy of the eye b) enlargement of anterior segment ......................... 12
Figure 2: Barriers to drug absorption ........................................................................... 15
Figure 3: Components of SLNs .................................................................................. 19
Figure 4: Method of SLN preparation .......................................................................... 20
Figure 5: Type of in-situ gelling based on gelling mechanism ...................................... 24
Figure 6: QbD approach to formulation development .................................................. 26
Figure 7: Examples of Fluoroquinolones ..................................................................... 30
Figure 8: Moxifloxacin structure .................................................................................. 31
Figure 9: Formulation strategy approach ....................................................................... 34
Figure 10: Overview of step involved in manufacturing process .................................... 59
Figure 11: Grading of skin reactions ............................................................................. 73
Figure 12: Grading Of ocular lesions ............................................................................ 74
Figure 13: Calibration curve plot in Methanol ................................................................. 78
Figure 14: Calibration curve plot in TDW ....................................................................... 78
Figure 15: Calibration curve plot in STF ....................................................................... 78
Figure 16: Lipid water partition coefficient ................................................................. 81
Figure 17: Process mapping for MOX SLNs to identify process parameters impacting quality attributes ................................................................. 84
Figure 18: Formulation parameters for MOX SLNs to identify formulation parameters impacting quality attributes ................................................................. 84
Figure 19: Screening studies reflecting CQA (EE) as a high shear homogenization time and high pressure homogenization cycle using lipids ........................................... 86
Figure 20: Screening studies reflecting CQA (EE) as a function of drug: lipid ratio and high pressure homogenization cycle ................................................................. 87
Figure 21: Screening studies reflecting CQA (in vitro release & EE) as a function of surfactant type

Figure 22: Screening studies reflecting CQA (Outlet Temperature) as a function of Chiller Temperature

Figure 23: Response surface plot showing relationship between factors Chiller temperature, HPH pressure, HPH cycle on CQA: Particle size

Figure 24: Response surface plot showing relationship between factors Chiller temperature, HPH pressure, HPH cycle on CQA: Entrapment Efficiency

Figure 25: Response surface plot showing relationship between factors Chiller temperature, HPH pressure, HPH cycle on CQA: Outlet Temperature

Figure 26: Desirability plot and deign space plot carried out for process optimization studies

Figure 27: Response surface plot showing relationship between factors Lipid: Drug & Percent gelling agent on CQA: Formulation temperature

Figure 28: Response surface plot showing relationship between factors Lipid: Drug, Lipid: Surfactant & Percent gelling agent on CQA: Entrapment Efficiency

Figure 29: Response surface plot showing relationship between factors Lipid: Drug, & Percent gelling agent on CQA: Release 0.5 h

Figure 30: Response surface plot showing relationship between factors Lipid: Drug, Lipid: Surfactant & Percent gelling agent on CQA: Release 8 h

Figure 31: Desirability plot and deign space plot carried out for process optimization studies

Figure 32: In vitro release profile formulation optimization design OPT 1-15

Figure 33: Ex vivo corneal permeability data of design space formulation wrt to IR solution

Figure 34: Apparent Permeability Coefficient of design space formulations

Figure 35: Attributes linked to patient compliance and its characterization measure
LIST OF FIGURES

Figure 36: Gelling temperature and gelling time observed for design space formulations .......................................................................................................................................................... 111

Figure 37: Viscosity observed for formulation at 25° C & 35° C on dilution .......... 114

Figure 38: Typical force-time plot of texture analyzer ........................................ 115

Figure 39: In vitro release and entrapment efficiency observed for OPT 7 formulations during hold time study .......................................................................................................................... 117

Figure 40: IR spectra of pure drug (MOX) ................................................................................................................................. 121

Figure 41: IR Spectra of Compritol Alone, SD, Physical Mix ............................................. 122

Figure 42: IR Spectra of Stearic Acid Alone, SD, Physical Mix .................................... 123

Figure 43: IR Spectra of Span 60 Alone, SD, Physical Mix ........................................ 124

Figure 44: IR Spectra of Poloxamer 407 Alone, SD, Physical Mix ............................. 125

Figure 45: IR Spectra of Mannitol alone, SD & Physical mix .................................. 126

Figure 46: IR spectra of formulation OPT-07-1 ......................................................... 127

Figure 47: X-RD spectra of API (MOX) ........................................................................ 128

Figure 48: X-RD spectra of solid dispersion (Drug + stearic acid) ......................... 128

Figure 49: X-RD spectra of solid dispersion (Drug + Compritol) ............................. 128

Figure 50: X-RD spectra of solid dispersion (Drug + Poloxamer) ............................. 129

Figure 51: X-RD spectra of solid dispersion (Drug + Span 60) ............................... 129

Figure 52: X-RD spectra of solid dispersion (Drug + Mannitol) .............................. 129

Figure 53: X-RD spectra of Formulation OPT-7-1 ..................................................... 130

Figure 54: DSC thermogram of API (MOX) .............................................................. 130

Figure 55: DSC thermogram of Stearic Acid ............................................................ 131

Figure 56: DSC thermogram of Compritol 888 ATO .............................................. 131

Figure 57: DSC thermogram of Span 60 ............................................................... 131

Figure 58: DSC thermogram of Poloxamer 407 ....................................................... 132
Figure 59: DSC thermogram of Mannitol ................................................................. 132

Figure 60: DSC thermogram of Formulation OPT-7-1 .............................................. 132

Figure 61: Antibacterial efficacy study optimized formulation OPT-07-1 wrt marketed eye drops against bacteria *S. aureus* ................................................................. 134

Figure 62: Antibacterial efficacy study optimized formulation OPT-07-1 wrt marketed eye drops against bacteria *B. subtilis* ................................................................. 134

Figure 63: Antibacterial efficacy study optimized formulation OPT-07-1 wrt marketed eye drops against bacteria *E. coli* ................................................................. 135

Figure 64: Fluorescence seen in aqueous humor after 4, 8, 12 & 16 h ......................... 138

Figure 65: The clinical presentations of eyes infected with *S. aureus* for control group, treatment with marketed formulation and after treatment with Hybrid formulation OPT-07-1 at initial, day 3 & 5th day ................................................................. 139

Figure 66: Disease severity in eyes infected with *S. aureus* for control group, treatment with marketed formulation and after treatment with Hybrid formulation OPT-07-1 at initial, day 1, 3 & 5th day of treatment ................................................................. 141

Figure 67: The clinical presentations of eyes infected with *S. aureus* for control group, treatment with marketed formulation and after treatment with Hybrid formulation OPT-07-1 at initial, day 3 & 5th day ................................................................. 144

Figure 68: Disease severity in eyes infected with *S. aureus* for control group, treatment with marketed formulation and after treatment with Hybrid formulation OPT-07-1 at initial, day 1, 3 & 5th day of treatment ................................................................. 145

Figure 69: Stability of lyophilized lipid nanoparticles under stability ......................... 148